Cyclopharm Ltd (CYC)

Currency in AUD
0.425
+0.040(+10.39%)
Closed·
CYC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4000.455
52 wk Range
0.3301.290
Key Statistics
Bid/Ask
0.42 / 0.45
Prev. Close
0.425
Open
0.4
Day's Range
0.4-0.455
52 wk Range
0.33-1.29
Volume
111.3K
Average Volume (3m)
69.53K
1-Year Change
-33.0709%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.020
Upside
+139.95%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Cyclopharm Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.020
(+139.95% Upside)

Cyclopharm Ltd Earnings Call Summary for Q3/2026

  • U.S. revenue surged 124% YoY to AUD $1.62M in Q3 2026; global 9M revenue rose 13.7% to AUD $25.9M with consumables now 76% of U.S. sales.
  • Monthly cash burn improved to AUD $900K from AUD $1.8M in H2 2025; cash on hand stood at AUD $9.6M with 110 systems ready for deployment.
  • U.S. installed base more than doubled to 84 systems from 40 at end-2025, driven by new lung-imaging guidelines spurring hospital adoption.
  • Management provided no formal guidance but cited growing pipeline conversions and 95% gross margins on consumables as key growth drivers ahead.
  • Shares rose 2.7% to $0.38, still 70% below 52-week high; analysts note company remains unprofitable despite improving revenue trajectory.
Last Updated: 29/10/2026, 11:36 am
Read Full Transcript

Earnings

Latest Release
23/08/2026
EPS / Forecast
-0.07 / --
Revenue / Forecast
17.52M / --
EPS Revisions
Last 90 days

CYC Income Statement

Compare CYC to Peers and Sector

Metrics to compare
CYC
Peers
Sector
Relationship
P/E Ratio
−2.9x−3.2x−0.3x
PEG Ratio
0.09−0.080.00
Price/Book
1.7x3.1x2.6x
Price / LTM Sales
1.6x2.3x2.8x
Upside (Analyst Target)
139.9%109.6%66.4%
Fair Value Upside
Unlock25.6%9.1%Unlock

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.24M1.78%950.75K
Other Institutional Investors
78.42M62.37%33.33M
Public Companies & Retail Investors
45.08M35.85%19.16M
Total
125.73M100.00%53.44M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Barings Acceptance Limited13.75%17,285,5737,346
Anglo Australian Christian And Charitable Fund10.51%13,211,3325,615

FAQ

What Is the Cyclopharm Ltd (CYC) Stock Price Today?

The Cyclopharm Ltd stock price today is 0.425 AUD.

What Stock Exchange Does Cyclopharm Ltd Trade On?

Cyclopharm Ltd is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Cyclopharm Ltd?

The stock symbol for Cyclopharm Ltd is "CYC."

What Is the Cyclopharm Ltd Market Cap?

As of today, Cyclopharm Ltd market cap is 53.440M AUD.

What Is Cyclopharm Ltd's Earnings Per Share (TTM)?

The Cyclopharm Ltd EPS (TTM) is -0.16.

From a Technical Analysis Perspective, Is CYC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Cyclopharm Ltd Stock Split?

Cyclopharm Ltd has split 3 times.

How Many Employees Does Cyclopharm Ltd Have?

Cyclopharm Ltd has 104 employees.

What is the current trading status of Cyclopharm Ltd (CYC)?

As of 01/11/2026, Cyclopharm Ltd (CYC) is trading at a price of 0.425 AUD, with a previous close of 0.425 AUD. The stock has fluctuated within a day range of 0.400 AUD to 0.455 AUD, while its 52-week range spans from 0.330 AUD to 1.290 AUD.

What Is Cyclopharm Ltd (CYC) Price Target According to Analysts?

The average 12-month price target for Cyclopharm Ltd is 1.020 AUD, with a high estimate of 1.01976959 AUD and a low estimate of 1.01976959 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +139.95% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.